A. Reis (Cortegaca, Portugal), Y. Adir (Haifa, Israel)
LATE-BREAKING ABSTRACT: Survival in patients with idiopathic, familial and anorexigen-associated pulmonary arterial hypertension in the modern management era
M. H. Humbert, G. S. Simonneau (Clamart, France)
|  |
The adverse effect of estrogen on bone morphogenetic protein receptor (BMPR) signal pathway in pulmonary arterial endothelial cells (PAEC)
H. Ichimori, S. Kogaki, H. Ishida, J. Narita, T. Uchikawa, S. Maekawa, S. Matsumoto, Y. Okada, K. Ozono (Suita, Japan)
| |
Parameters influencing pre test probability of pulmonary embolism (PE)
S. Chandramouli, A. Dakak, K. McPartland, M. Babores (Macclesfield, United Kingdom)
|  |
Diagnostic yield of CT PA and characteristics of patients with suspected pulmonary embolism
M. Saleem, S. Sreenivas, J. Salmon, R. Rizvi, A. O‘Driscoll (Naas, Ireland)
| |
Management of acute pulmonary thrombo-embolic disease (PTE) linking mortality risk to treatment strategies
N. Ahmad, Z. Ammen, K. Srinivasan, H. Moudgil (Telford, United Kingdom)
| |
Intravenous line complications during continuous iloprost therapy using directly inserted subclavian catheters
U. Treder, M. Fischler, L. C. Huber, R. Speich, S. Ulrich (Zurich, Switzerland)
| |
Factors affecting early and late mortality in pulmonary embolism
A. Singanayagam, J. Chalmers, C. Scally, M. Al-Khairalla, L. Leitch, A. Hill (Edinburgh, Dundee, United Kingdom)
| |
Pulmonary hypertension and diastolic left ventricular dysfunction – clinical and hemodynamic characteristics
Y. Adir, R. Walff, D. Weiler, B. Lewis, O. Amir (Haifa, Israel)
| |
Four year experience of a dedicated connective tissue disorder pulmonary hypertension clinic
R. Lee, R. Martin, G. Coghlan, D. D‘Cruz (London, United Kingdom)
| |
²The mimicker² pulmonary artery sarcoma
P. Domingo, M. P. Mateo, T. De Guia‘ (Quezon City, Philippines)
| |
Lung hypertension: developmental mechanisms and assesment therapeutic action efficiency
O. Korolkova (Voronezh, Russian Federation)
| |
The role of peroxisome proliferator-activated receptor γ in pulmonary hypertension
W. Han, X. Zhou, H. Tang (Qingdao, Shanghai, China)
| |
Natriuretic peptides levels and heart remodeling in different forms of pulmonary hypertension
Y. A. Andreeva, M. A. Saidova, T. V. Martynyuk, V. P. Masenko, A. V. Volkov, I. Y. Chazova (Moscow, Russian Federation)
| |
A hereditary hemorrhagic telengiectasia case applied transcathater embolization for bilateral large pulmonary arteriovenous malformations
K. Rollas, U. Yilmaz Turay, C. Biber, A. Yilmaz, L. Yilmaz Aydin, Y. Erdogan (Ankara, Turkey)
| |
Exercise training in pulmonary hypertension improves beta-adrenergic signaling of the right ventricle
F. De Man, M. L. Handoko, N. Hamdani, P. Postmus, W. van der Laarse, N. Westerhof, W. Paulus, J. van der Velden, A. Vonk-Noordegraaf (Amsterdam, Netherlands)
| |
Long term benefit of sildenafil in patients with pulmonary hypertension
H. Ranu, W. Barker, P. Nash, M. Wilde, B. Madden (London, United Kingdom)
| |
Idiopathic pulmonary hypertension: x-ray, morphological, and angiographic comparisons
V. Lazutkina, I. Korobkova, K. Zykov (Moscow, Russian Federation)
| |
The heat shock protein 90 inhibitor, 17-AAG, ameliorates pulmonary arteriolar and right ventricular hypertrophy in monocrotaline-induced pulmonary arterial hypertension
C. Dimitropoulou, M. L. Meadows, C. Snead, S. A. Barman, J. D. Catravas (Augusta, United States Of America)
| |
Chronic hypoxia-induced pulmonary hypertension is linked to a decrease in the soluble epoxide hydrolase
B. Keserü, B. Fisslthaler, N. Weissmann, I. Fleming (Frankfurt am Main, Giessen, Germany)
| |